This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ionis Pharmaceuticals, Inc.
Drug Names(s): ISIS 304801, ISIS-APOCIIIRx, IONIS-APOCIIIRx
Description: ISIS-APOCIIIRx is an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. ISIS-APOCIIIRx inhibits the production of apolipoprotein C-III (apoC-III), a traditionally undruggable target that plays a central role in the regulation of triglycerides.ApoC-III is a potent inhibitor of lipoprotein lipase (LPL) catalyzed lipolysis of triglyceride rich lipoproteins, such as VLDL. It also inhibits hepatic lipase which is involved in the conversion of dense VLDL to IDL. ApoC-III additionally inhibits receptor-mediated uptake of lipoprotein remnants by the liver.
Additional information available to subscribers only: